Loading…
This event has ended. Create your own event on Sched.
November 21-30 – Sign-ups/changes open. After December 1, schedules will be frozen.
Friday January 10, 2025 1:55pm - 3:10pm PST
WRC
It takes an average of $1.3 billion and more than 10 years to bring a new medicine to the point of applying for FDA approval. After pursuing this long and often tortuous path, the prospects are risky, and the FDA faces a binary choice: Grant marketing authorization, or reject the application?

What does the drug development process entail, and why is it so long, expensive, and complex? What is FDA's role in protecting American consumers and the public? How are the concepts of "benefit" and "risk" used to provide a framework for these decisions?

In this interactive session, you will learn the basics of the drug development process, including the role of the FDA in deciding whether to allow access to new drugs. Students will work in groups to evaluate whether a new drug should be "approved", and, if so, under what conditions.
Facilitators
avatar for Thomas Chalberg

Thomas Chalberg

Founder & Managing Director, Polymerase Capital
Thomas W. Chalberg, PhD is an investor, scientist, and biotechnology entrepreneur. He is currently Managing Director of Polymerase Capital, where his investments have included Genascence Corporation and Exhaura. Prior to this, Dr. Chalberg was the Founder & CEO of SightGlass Vision... Read More →
Friday January 10, 2025 1:55pm - 3:10pm PST
WRC
Feedback form is now closed.
Share Modal

Share this link via

Or copy link